CITRANATAL 90 DHA Rx
Generic Name and Formulations:
Thiamine 3mg, riboflavin 3.4mg, niacinamide 20mg, pyridoxine HCl 20mg, folic acid 1mg, Vit. C 120mg, Vit. D3 400 IU, Vit. E 30 IU, calcium (as citrate) 160mg, copper (as oxide) 2mg, iodine (as potassium iodide) 150mcg, iron (as carbonyl) 90mg, zinc (as oxide) 25mg, docusate sodium 50mg; scored tabs. Docosahexaenoic acid (DHA) 300mg; caps; contains gelatin.
Mission Pharmacal Company
Indications for CITRANATAL 90 DHA:
Nutritional supplement in pregnancy, prenatal, and postnatal periods.
1 tab and 1 DHA cap daily.
Treatment of pernicious anemia or other megaloblastic anemias. Hemochromatosis.
Folic acid may mask pernicious anemia. DHA (>3g/day): bleeding diatheses.
Iron, calcium block tetracycline absorption. Antagonizes levodopa. DHA: avoid anticoagulants.
CitraNatal Assure, CitraNatal DHA, CitraNatal 90 DHA blister pack (5 tabs + 5 caps)—6; CitraNatal Rx tabs—100; CitraNatal Harmony—30; CitraNatal B-Calm blister pack (5 tabs + 10 tabs)—6
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder
- Duration of Untreated Depression Predicts Depression Severity
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV